For the quarter ending 2026-03-31, APLS had -$61,033K decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income/(loss) | 18,656 | -58,951 | 215,715 | -42,151 |
| Share-based compensation expense | 25,173 | 21,246 | 28,186 | 27,197 |
| Depreciation expense | 291 | 327 | 339 | 446 |
| Amortization of discounts for credit facility | -511 | - | 556 | 534 |
| Amortization of discounts for credit facility and convertible notes | - | 2,496 | - | - |
| Amortization of discounts for convertible notes | -78 | - | 80 | 80 |
| Accounts receivable | 74,068 | 20,674 | 131,403 | -21,118 |
| Inventory | -18,806 | 8,658 | -5,402 | 26,008 |
| Prepaid assets | - | - | 2,384 | -7,953 |
| Other current assets | - | - | -9,787 | 6,838 |
| Prepaid and other current assets | 11,270 | 8,087 | - | - |
| Other assets | 292 | -120 | 4,440 | -61 |
| Right-of-use assets and lease liabilities | -16 | -143 | -113 | 215 |
| Accounts payable | -7,741 | 18,195 | -15,638 | -1,045 |
| Accrued expenses and other liabilities | -31,166 | 25,585 | 7,075 | 22,883 |
| Other current liabilities | - | - | 0 | - |
| Other liabilities | - | - | -4,694 | - |
| Net cash used in operating activities | -60,966 | -14,176 | 108,468 | 4,445 |
| Purchase of property and equipment | - | 108 | 148 | 49 |
| Net cash used in investing activities | - | -108 | -148 | -49 |
| Proceeds from exercise of stock options | 86 | 100 | 797 | 4,367 |
| Proceeds from issuance of common stock under employee share purchase plan | - | 1,159 | 0 | 2,191 |
| Payments of employee tax withholding related to equity-based compensation | 22 | 0 | 4 | 0 |
| Net cash provided by financing activities | 64 | 1,259 | 793 | 6,558 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | -131 | 184 | 22 | 685 |
| Net decrease in cash, cash equivalents and restricted cash | -61,033 | -12,841 | 109,135 | 11,639 |
| Cash, cash equivalents and restricted cash at beginning of period | 467,760 | 480,601 | 371,466 | 359,827 |
| Cash, cash equivalents and restricted cash at end of period | 406,727 | 467,760 | 480,601 | 371,466 |
Apellis Pharmaceuticals, Inc. (APLS)
Apellis Pharmaceuticals, Inc. (APLS)